Kimia Biosciences , a prominent player in the Indian pharmaceutical sector, has released its unaudited financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 14, 2025, as per the regulatory filing with the BSE.

Financial Highlights

The company's performance for the second quarter shows resilience in a challenging economic environment. Here's a breakdown of the key financial metrics:

Cash Flow and Financial Position

For the half-year period, Kimia Biosciences reported:

While the company has shown positive cash flow from operations, it's worth noting that Kimia Biosciences faced some financial challenges, including:

• Increased borrowings
• Higher finance costs

These factors suggest that the company may be navigating through a period of financial adjustments or expansion that requires additional capital.

Corporate Governance and Compliance

The financial results were approved in a Board meeting that commenced at 7:00 PM and concluded at 8:00 PM on November 14, 2025. This meeting was held at the company's corporate office located at 974, 9th floor, Aggarwal Millennium Tower-II, Netaji Subhash Place, New Delhi-110034.

In compliance with SEBI regulations, the company has:

1. Approved the unaudited financial results on a standalone basis for Q2 and H1.
2. Taken on record the limited review report issued by the statutory auditors.

Market Implications

The reported net profit of Rs 101.40 lakhs indicates that Kimia Biosciences has maintained profitability despite the increased financial costs. This could be viewed positively by investors, especially considering the challenging economic conditions many businesses are facing.

However, the increase in borrowings and finance costs warrants attention. Investors and analysts may want to keep an eye on how the company manages its debt and uses the borrowed funds to drive growth or operational improvements in the coming quarters.

The pharmaceutical sector, being essential and relatively resilient, often attracts investor interest. Kimia Biosciences' performance in this context may be of particular interest to those tracking the Indian pharma industry's growth and challenges.

Kimia Biosciences Limited, a pharmaceutical company, has announced a significant change in its leadership. Mr. Prasad Raju (Ramakrishnavara Prasada Raju Mantena), a director of the company, has resigned from his position effective November 12, 2025. The resignation comes as a result of medical advice and personal well-being concerns.

Key Details of the Resignation

Company's Response

Kimia Biosciences Limited has accepted Mr. Raju's resignation and relieved him from his duties on November 12, 2025. The company made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director's Statement

In his resignation letter, Mr. Raju expressed his gratitude to the Board and his colleagues. He stated, "It has been an honour to serve and contribute to the growth of Kimia Biosciences Limited." Mr. Raju also assured his full support in ensuring a smooth transition of duties and responsibilities.

Impact and Next Steps

The company has not provided information on a successor but has confirmed that there are no material reasons for the resignation other than those mentioned in Mr. Raju's letter. The Board will likely begin the process of finding a suitable replacement to ensure continuity in the company's operations and strategic direction.

This change in directorship comes at a time when pharmaceutical companies are facing increasing challenges and opportunities in the global market. Stakeholders will be watching closely to see how Kimia Biosciences navigates this transition and continues to pursue its business objectives.

As per regulatory requirements, Kimia Biosciences Limited has duly informed the BSE Limited of this development, maintaining transparency with its investors and the market at large.